BioAge Labs (NASDAQ:BIOA) Shares Down 4.1% – What’s Next?

BioAge Labs, Inc. (NASDAQ:BIOA) shares traded down 4.1% during trading on Thursday . The company traded as low as $18.46 and last traded at $19.3030. 852,431 shares were traded during mid-day trading, a decline of 20% from the average session volume of 1,070,947 shares. The stock had previously closed at $20.12.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research report on Thursday, October 30th. Citigroup lifted their target price on shares of BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, Wall Street Zen raised BioAge Labs from a “sell” rating to a “hold” rating in a research note on Sunday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, BioAge Labs presently has an average rating of “Hold” and a consensus target price of $15.00.

BioAge Labs Price Performance

The company has a 50 day moving average of $12.98 and a 200-day moving average of $8.00. The company has a market capitalization of $677.57 million, a P/E ratio of -12.43 and a beta of 1.38.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The business had revenue of $2.05 million during the quarter.

Insider Activity at BioAge Labs

In other BioAge Labs news, insider Paul D. Rubin sold 18,000 shares of the business’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $12.00, for a total transaction of $216,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kristen Fortney sold 233,107 shares of the stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $18.12, for a total transaction of $4,223,898.84. Following the completion of the transaction, the chief executive officer directly owned 976,949 shares of the company’s stock, valued at approximately $17,702,315.88. The trade was a 19.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 347,004 shares of company stock worth $5,673,859 over the last quarter. Corporate insiders own 20.82% of the company’s stock.

Institutional Investors Weigh In On BioAge Labs

Hedge funds and other institutional investors have recently bought and sold shares of the business. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of BioAge Labs during the second quarter valued at approximately $27,000. Russell Investments Group Ltd. bought a new stake in shares of BioAge Labs in the third quarter worth approximately $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of BioAge Labs by 85.6% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after purchasing an additional 5,976 shares during the last quarter. Public Employees Retirement System of Ohio bought a new position in BioAge Labs during the second quarter valued at approximately $57,000. Finally, Intech Investment Management LLC bought a new position in BioAge Labs during the second quarter valued at approximately $60,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.